Andreas Muhs

USPTO Granted Patents = 34 (Patent Applications = 28)

CIPO Patents = 13 (Patent Applications = 1)

EPO Patents = 26 (Patent Applications = 32)

Average Co-Inventor Count = 4.5

ph-index = 9

Forward Citations = 254(Granted Patents)

Location History:

Pully/VD, CH (2014 - 2015)
Pully, CH (2010 - 2019)
Cugy, CH (2015 - 2024)

Company Filing History:

Katholieke Universiteit Leuven

patents

4. 5 out of 159

Janssen Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12324855 - Method of safe administration of phosphorylated Tau peptide vaccine (2025-06-10),

2. 11958889 - Compositions of phosphorylated tau peptides and uses thereof (2024-04-16),

3. 11684576 - Method of safe administration of phosphorylated tau peptide vaccine (2023-06-27),

4. 11591377 - Heterologous administration of tau vaccines (2023-02-28),

5. 11352419 - Anti-tau antibodies and methods of use (2022-06-07),

6. 11124552 - Compositions of phosphorylated tau peptides and uses thereof (2021-09-21),

7. 10836817 - Anti-Tau antibodies and methods of use (2020-11-17),

8. 10500207 - Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins (2019-12-10),

9. 10100104 - Methods of diagnosing tau-protein-associated disease (2018-10-16),

10. 10066010 - Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising Tau (2018-09-04),

11. 9701660 - 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system (2017-07-11),

12. 9687447 - Method for preparing liposome-based constructs (2017-06-27),

13. 9657091 - Humanized tau antibody (2017-05-23),

14. 9598485 - Anti-tau antibodies and methods of use (2017-03-21),

15. 9585956 - Polynucleotides encoding anti-amyloid beta monoclonal antibodies (2017-03-07),

Title: Innovations by Andreas Muhs in Neurodegenerative Disease Research

Introduction

Andreas Muhs is an accomplished inventor based in Pully, Switzerland, with a remarkable portfolio that includes 33 patents. His work primarily focuses on the development of innovative solutions for treating neurodegenerative diseases, particularly Alzheimer's disease. His recent patents have introduced new methods for administering therapeutic agents, which has significant implications for future medical treatments.

Latest Patents

Among his latest patents is a groundbreaking technology involving compositions of phosphorylated tau peptides and their applications. This patent describes the use of liposomes containing these peptides, which can be conjugated to immunogenic carriers. The pharmaceutical compositions outlined in this patent aim to treat or prevent neurodegenerative diseases, offering new hope for conditions like Alzheimer's Disease. Furthermore, another patent details a method for the safe administration of a phosphorylated tau peptide vaccine. This method is designed to induce an immune response, specifically anti-phosphorylated Tau antibodies, without causing severe adverse effects in humans. It involves the use of liposomes that incorporate a toll-like receptor 4 agonist along with the Tau phosphopeptides.

Career Highlights

Andreas Muhs has worked with prominent companies in the biotech field, including AC Immune SA and Genentech, Inc. Throughout his career, he has contributed significantly to advancing the understanding and treatment of neurodegenerative disorders through his innovative inventions and research.

Collaborations

In his professional journey, Muhs has collaborated with distinguished individuals such as Andrea M. Pfeifer and Maria Pihlgren. These partnerships have likely provided synergistic effects, enhancing the research and development of therapies for complex diseases.

Conclusion

Andreas Muhs is a notable inventor whose contributions to the field of neurodegenerative disease research are both innovative and essential. With a strong foundation of patents and collaborations, his work continues to pave the way for new treatment strategies, potentially transforming the lives of those affected by devastating conditions like Alzheimer's Disease. His inventive spirit and commitment to advancing medical science reflect the true essence of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.